Combining bioreductive drugs and radiation for the treatment of solid tumors

被引：22

作者：

Stratford, IJ ^{[1
]}

Williams, KJ ^{[1
]}

Cowen, RL ^{[1
]}

Jaffar, M ^{[1
]}

机构：

[1] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England

来源：

SEMINARS IN RADIATION ONCOLOGY | 2003年 / 13卷 / 01期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1053/srao.2003.50008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Methods now exist for the identification of human tumors that contain significant numbers of hypoxic cells and are thereby suitable for treatment with bioreductive drugs to eliminate this refractory cell population. However, to fully exploit the potential of bioreductive drugs, they will need to be used in combination with other modalities likely to target the proliferating aerobic cells in the tumor. Radiation is the treatment that is most effective in killing aerobic cells; therefore, the present report reviews the available preclinical data on combined radiation/bioreductive drug treatments. Copyright 2003, Elsevier Science (USA). All rights reserved.

引用

页码：42 / 52

页数：11

共 84 条

[1] BIOREDUCTIVE DRUGS FOR CANCER-THERAPY - THE SEARCH FOR TUMOR SPECIFICITY [J].

ADAMS, GE ;

STRATFORD, IJ .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 29 (02) :231-238

[2]

Airley R, 2001, CLIN CANCER RES, V7, P928

[3] Exploring the mechanistic aspects of mitomycin antibiotic bioactivation in Chinese hamster ovary cells overexpressing NADPH:cytochrome C (P-450) reductase and DT-diaphorase [J].

Belcourt, MF ;

Hodnick, WF ;

Rockwell, S ;

Sartorelli, AC .

ADVANCES IN ENZYME REGULATION, VOL 38, 1998, 38 :111-133

[4] SR-4233 CYTOTOXICITY AND METABOLISM IN DNA REPAIR-COMPETENT AND REPAIR-DEFICIENT CELL-CULTURES [J].

BIEDERMANN, KA ;

WANG, J ;

GRAHAM, RP ;

BROWN, JM .

BRITISH JOURNAL OF CANCER, 1991, 63 (03) :358-362

[5] PHARMACOKINETIC CONTRIBUTION TO THE IMPROVED THERAPEUTIC SELECTIVITY OF A NOVEL BROMOETHYLAMINO PRODRUG (RB-6145) OF THE MIXED-FUNCTION HYPOXIC CELL SENSITIZER CYTOTOXIN A-(1-AZIRIDINOMETHYL)-2-NITRO-1H-IMIDAZOLE-1-ETHANOL (RSU-1069) [J].

BINGER, M ;

WORKMAN, P .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 29 (01) :37-47

[6] ASSESSING THE BIOREDUCTIVE EFFECTIVENESS OF THE NITROIMIDAZOLE RSU1069 AND ITS PRODRUG RB6145 - WITH PARTICULAR REFERENCE TO IN-VIVO METHODS OF EVALUATION [J].

BREMNER, JCM .

CANCER AND METASTASIS REVIEWS, 1993, 12 (02) :177-193

[7] Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954 [J].

Bridgewater, JA ;

Springer, CJ ;

Knox, RJ ;

Minton, NP ;

Michael, NP ;

Collins, MK .

EUROPEAN JOURNAL OF CANCER, 1995, 31A (13-14) :2362-2370

[8] SR-4233 (TIRAPAZAMINE) - A NEW ANTICANCER DRUG EXPLOITING HYPOXIA IN SOLID TUMORS [J].

BROWN, JM .

BRITISH JOURNAL OF CANCER, 1993, 67 (06) :1163-1170

[9]

BROWN JM, 1990, CANCER RES, V50, P7745

[10] TUMOR HYPOXIA - THE PICTURE HAS CHANGED IN THE 1990S [J].

BROWN, JM ;

GIACCIA, AJ .

INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 1994, 65 (01) :95-102

← 1 2 3 4 5 6 7 8 9 →